SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: Rick Dudley who wrote (35496)3/19/2003 4:11:05 PM
From: Saulamanca  Read Replies (1) | Respond to of 59879
 
I agree on a double from here.

Good luck.



To: Rick Dudley who wrote (35496)4/25/2003 2:42:15 PM
From: Saulamanca  Read Replies (1) | Respond to of 59879
 
Rick, Do you like this news about AVII? -g-

timesonline.co.uk

THE first drug to combat the Sars virus could be available for treating patients within months, after new research in the United States.

Early trials at the US National Institutes of Health suggest that the antiviral therapy, developed by AVI BioPharma in Oregon, is highly effective at killing the coronavirus that is thought to cause Sars.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News